Journal Article Summary
The article examines the long-term effects of semaglutide, a medication used for weight management, in individuals with obesity but without diabetes. This research is significant because obesity is a major global health issue linked to various chronic diseases, including cardiovascular disease and diabetes. The study aims to provide insights into how semaglutide can help individuals achieve and maintain weight loss, which is crucial for improving overall health and reducing the risk of related health complications.
In the SELECT trial, which involved over 17,600 adults with preexisting cardiovascular disease, participants were randomly assigned to receive either semaglutide or a placebo. The results showed that those taking semaglutide experienced a significant average weight loss of 10.2% over 208 weeks, compared to just 1.5% for the placebo group. Additionally, improvements in waist circumference and waist-to-height ratio were observed, indicating better body composition. A higher percentage of participants in the semaglutide group achieved clinically meaningful weight loss milestones, such as losing 5% or more of their body weight.
Despite these promising findings, the study has limitations, including its design as a cardiovascular outcomes trial rather than a primary weight-loss trial, which may affect the generalizability of the results. Patients should be aware that individual responses to semaglutide can vary, and some may experience side effects leading to treatment discontinuation. It is essential for readers to discuss any weight management strategies, including the use of semaglutide, with their healthcare professionals to ensure it aligns with their health needs and conditions.
Medication Safety Note
This journal article summary is provided for educational purposes only and is not medical advice. Always consult a licensed healthcare professional before starting, stopping, or changing any medication.
Article Cited
- Ryan Donna H., Lingvay Ildiko, Deanfield John, Kahn Steven E., Barros Eric, Burguera Bartolome, Colhoun Helen M., Cercato Cintia, et al.. Long-term weight loss effects of semaglutide in obesity without diabetes in the SELECT trial. Nature Medicine 2024. DOI: 10.1038/s41591-024-02996-7. PMID: 38740993. PMCID: PMC11271387.
Featured Pill Pals Product
Semaglutide with B-12 --- 10 mg / 2 mg / 4 ml --- 4 ml vial --- Weight Loss Glucagon-Like Peptide-1 (GLP-1)
Semaglutide with B-12 — 10 mg / 2 mg / 4 ml — 4 ml vial — Weight Loss Glucagon-Like Peptide-1 (GLP-1) is available through Pill Pals Pharmacy with cash-pay pharmacy pricing and free shipping where available. Prescription required.
Request a prescription transfer and our pharmacy team will help coordinate the next step.
